Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
On September 23, 2021, Novavax hosted HM King Carl XVI Gustaf and HM Queen Silvia at its Uppsala facility to discuss the progress of NVX-CoV2373, its COVID-19 vaccine candidate. The visit highlighted Novavax's commitment to global vaccination efforts, with a focus on its patented Matrix-M™ adjuvant, enhancing immune response. NVX-CoV2373 has shown high efficacy in Phase 3 trials, including 100% efficacy against severe disease. Novavax is also advancing its NanoFlu™ vaccine and is committed to addressing urgent global health needs.
- NVX-CoV2373 demonstrated 100% protection against moderate and severe COVID-19 disease in the PREVENT-19 trial.
- The vaccine candidate has overall efficacy rates of 90.4% in trials.
- Matrix-M™ adjuvant enhances immune response, supporting multiple vaccine candidates.
- None.
GAITHERSBURG, Md., Sept. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, hosted HM King Carl XVI Gustaf and HM Queen Silvia for a visit to Novavax AB, the company's Uppsala, Sweden manufacturing affiliate on Thursday, September 23. The visit included a discussion of NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, and the company's role in combatting the global pandemic.
"We applaud the royal family for their exceptional leadership in supporting vaccination efforts to end the pandemic both in Sweden and globally," said Magnus Sävenhed, Managing Director, Novavax AB. "Novavax AB was delighted to share an overview of our progress and operations as we continue to grow our presence in Uppsala and build a global vaccine arsenal in the fight against COVID-19."
One of two Novavax-owned manufacturing affiliates, Novavax AB produces the Company's patented saponin-based Matrix-M™ adjuvant, a key component in several vaccine candidates that has been shown to improve immune responses and enable vaccine dose-sparing. It is currently being evaluated in vaccine candidates, including NVX-CoV2373, NanoFlu™, a recently announced investigational COVID-NanoFlu Combination Vaccine, and in clinical studies of several malaria vaccines.
About NVX-CoV2373
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 microgram antigen and 50 microgram Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels.
About NanoFlu™
NanoFlu™ is a quadrivalent recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced in Novavax' SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences and contains Novavax' patented saponin-based Matrix-M adjuvant.
About Matrix-M™ Adjuvant
Novavax' patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, the ongoing development of NVX-CoV2373, and other Novavax vaccine product candidates, the growth of Novavax AB and the role that Novavax may play in helping combat the COVID-19 pandemic are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; challenges effectively managing our growth and increased complexity of our operations; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-hosts-hm-king-carl-xvi-gustaf-and-hm-queen-silvia-of-sweden-during-royal-visit-to-uppsala-county-301384735.html
SOURCE Novavax, Inc.
FAQ
What is NVAX's NVX-CoV2373 vaccine candidate?
When did Novavax host the royal family?
What are the key results from the NVX-CoV2373 trials?
What is the significance of Matrix-M™ adjuvant?
What is Novavax's commitment towards global health?
